The Statistics say between $182-$253 (1 year)
This Looks like it can Happen in 1 Year.
That will depend on their Progress.
Let's see what will happen in 2023,
but it looks ok to hold for the next 5 Years or more
BioNTech aims to develop the first mRNA-based vaccine for Malaria
prevention with the initiation of a clinical trial by end of 2022
BioNTech is evaluating sustainable mRNA vaccine production capacities in Africa;
the Company’s efforts are supported by the joint convening powers of the World Health Organization (WHO)
and the Africa Centers for Disease Control and Prevention (Africa CDC)
BioNTech’s Malaria project is part of the ‘eradicate malaria’ initiative,
led by the kENUP Foundation, to accelerate the eradication of Malaria
Disclaimer:
Just my Idea! Find your Trading Ideas and learn and study more!
This Looks like it can Happen in 1 Year.
That will depend on their Progress.
Let's see what will happen in 2023,
but it looks ok to hold for the next 5 Years or more
BioNTech aims to develop the first mRNA-based vaccine for Malaria
prevention with the initiation of a clinical trial by end of 2022
BioNTech is evaluating sustainable mRNA vaccine production capacities in Africa;
the Company’s efforts are supported by the joint convening powers of the World Health Organization (WHO)
and the Africa Centers for Disease Control and Prevention (Africa CDC)
BioNTech’s Malaria project is part of the ‘eradicate malaria’ initiative,
led by the kENUP Foundation, to accelerate the eradication of Malaria
Disclaimer:
Just my Idea! Find your Trading Ideas and learn and study more!
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.